**Supplementary Tables**

Supplementary Table 1: Participating clinical sites.

|  |  |
| --- | --- |
| Site | N=503 (100%) |
| Urologic Research and Consulting LLC | 137 (27.2%) |
| Johns Hopkins University | 84 (16.7%) |
| Delaware Valley Urology | 70 (13.9%) |
| Associated Urologists of North Carolina | 67 (13.3%) |
| Urology of Virginia, PLLC | 41 (8.2%) |
| Five Valleys Urology | 38 (7.6%) |
| NYU Urology Associates | 25 (5%) |
| Comprehensive Medical Center | 12 (2.4%) |
| 21st Century Oncology | 11 (2.2%) |
| Premier Urology Group | 6 (1.2%) |
| Manhattan Medical Research | 5 (1%) |
| UTHSCSA - Dept. of Urology | 3 (0.6%) |
| Columbia University Medical Center | 2 (0.4%) |
| Carolina Urologic Research Center | 2 (0.4%) |

Supplementary Table 2: Classification performances for the second validation cohort (N=503) are given in percent for EPI cut points of 5, 10, 15.6, 20, 25, 30 and 35.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | EPI: 5 | EPI: 10 | **EPI: 15.6** | EPI: 20 | EPI: 25 | EPI: 30 | EPI: 35 |
| Prevalence | 31.4 | 31.4 | **31.4** | 31.4 | 31.4 | 31.4 | 31.4 |
| % Samples < Cutpoint | 1.0 | 7.2 | **20.1** | 30.8 | 39.6 | 50.5 | 59.2 |
| Sensitivity | 100.0 | 98.1 | **93.0** | 89.2 | 81.6 | 67.1 | 57.0 |
| Specificity | 1.4 | 9.6 | **26.1** | 40.0 | 49.3 | 58.6 | 66.7 |
| NPV | 100.0 | 91.7 | **89.1** | 89.0 | 85.4 | 79.5 | 77.2 |
| PPV | 31.7 | 33.2 | **36.6** | 40.5 | 42.4 | 42.6 | 43.9 |
| Accuracy | 32.4 | 37.4 | **47.1** | 55.5 | 59.4 | 61.2 | 63.6 |